The AD-CSF-Index Discriminates Alzheimer s Disease Patients from Healthy Controls: A Validation Study
|
|
- Eustace Hunt
- 6 years ago
- Views:
Transcription
1 Journal of Alzheimer s Disease 36 (2013) DOI /JAD IOS Press 67 The AD-CSF-Index Discriminates Alzheimer s Disease Patients from Healthy Controls: A Validation Study Jose L. Molinuevo a,b,c,1,, Juan Domingo Gispert c,1, Bruno Dubois d, Michael T. Heneka e, Alberto Lleo f, Sebastiaan Engelborghs g, Jesús Pujol h, Leonardo Cruz de Souza d, Daniel Alcolea f, Frank Jessen i, Marie Sarazin d, Foudil Lamari j, Mircea Balasa a, Anna Antonell a,b and Lorena Rami a,b a Alzheimer s Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Barcelona, Spain b Institut d Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain c BarcelonaBeta Brain Research Centre, Pasqual Maragall Foundation, Barcelona, Spain d Alzheimer Institute, Research and Resource Memory Centre, AP-HP, Pitié-Salpêtrière Hospital, Paris, France e Neurology Department, University of Bonn, Germany f Neurology Department, Hospital Sant Pau, Barcelona, CIBERNED, Spain g Reference Centre for Biological Markers of Dementia (BIODEM), University of Antwerp, Antwerp, Belgium h CRC-Mar, Hospital del Mar, CRC Corporació Sanitària, Barcelona, Spain i Department of Psychiatry, University of Bonn, Bonn, Germany j Department of Metabolic Biochemistry, AP-HP, Pitiá-Salpêtrière Hospital, Paris, France Handling Associate Editor: Piotr Lewczuk Accepted 2 March 2013 Abstract. Background: Cerebrospinal fluid (CSF) biomarkers of Alzheimer s disease (AD) show an acceptable diagnostic sensitivity and specificity; however, their interpretation and ease of use is far from optimal. Objective: To study and validate the diagnostic accuracy of an easy-to-use normalized CSF biomarker index, the AD-CSF-index, in different European populations. Methods: A total of 342 subjects, 103 healthy controls and 239 AD patients, from four European memory clinics were included. The AD-CSF-index was constructed from the addition of normalized values between the minimum and maximum of amyloid and tau protein levels. The diagnostic accuracy, receiver operating characteristic, and regression analysis of the AD-CSF-index and other composite indices were evaluated in this study. Results: AD patients presented a significantly higher AD-CSF-index than healthy subjects (control = ; AD = ; p < 0.001). The AD-CSF-index obtained a sensitivity of 88.6% at 85% specificity and also showed a significantly higher diagnostic power (p < 0.05) than the individual CSF biomarkers and other studied indices. The performance of the AD-CSF-index was very similar between ELISA and MesoScale measurements. Cut-off values of approximately 0.75 provided the lowest achievable overall classification errors and a cut-off point of about 0.95 consistently provided specificities above 85%. 1 Both authors contributed equally to this manuscript. Correspondence to: José Luis Molinuevo, M.D., Alzheimer s Disease and Other Cognitive Disorders Unit, Hospital Clínic, Villarroel 170, and Fundació Pasqual Maragall, 08036, Barcelona, Spain. Tel.: ; Fax: ; jlmoli@clinic.ub.es. ISSN /13/$ IOS Press and the authors. All rights reserved
2 68 J.L. Molinuevo et al. / Validation of the AD-CSF-Index Conclusion: The AD-CSF-index represents a novel approach, combining normalized CSF values, for the biological diagnosis of AD. The AD-CSF-index presents an optimal AUC with high sensitivity and specificity and seems to be a simple and intuitive way to interpret AD CSF biomarker results even from different analytical platforms. Keywords: Alzheimer s disease, biomarkers, cerebrospinal fluid, diagnostic accuracy, sensitivity, specificity INTRODUCTION Alzheimer s disease (AD) has been traditionally conceptualized as a clinico-pathological disease, requiring for its definite diagnosis the presence of a characteristic pathology together with a dementia clinical picture [1]. The main AD pathological lesions are neurofibrillary tangles and senile plaques formed by neuronal accumulations of abnormal tau filaments and extracellular deposits of amyloid fibrils respectively. Cerebrospinal fluid (CSF) studies measuring A 1-42 (A ) and total tau (t-tau) protein levels in AD patients with confirmed pathology have demonstrated that abnormal levels of both biomarkers constitute a specific signature of the underlying AD-related pathology [2, 3]. In that sense, a promising approach to increase diagnostic accuracy for AD is the use of CSF biomarkers, together with specific clinical symptomatology [4, 5]. Therefore, implementation of new criteria that captures both clinical and biological aspects of the disease has shifted the diagnostic paradigm toward a clinico-biological approach allowing an earlier and more specific detection of the disease [6]. However, although CSF biomarkers show an acceptable sensitivity and specificity to diagnose AD [7, 8], tau, phosphorylated tau (p-tau), and A concentrations considerably overlap between controls and patients [9]. To enhance discrimination power, combinations of these biomarkers into a single value have been proposed [10]. Examples of this approach are the ratios of tau or p-tau to A [11, 12] or the AD CSF profile derived by Hulstaert and colleagues [8]. These indices present higher diagnostic power than the individual CSF biomarkers [6, 13, 14] and prognostic capacity to predict cognitive decline in non-demented elderly subjects [15 17]. In that sense, we have recently developed a novel and easy way to calculate a CSF biomarker index that captures the biochemical changes along the AD continuum [18]. The AD-CSF-index is basically the normalization of A, tau, or p-tau values, which are then added into a single value (range from 0 to 2) to express the possibility of having AD with high sensitivity and specificity [18]. AD patients had a significantly higher AD-CSF-index than healthy subjects, which resulted in a sensitivity of 92% and a specificity of 89% in the discrimination of AD patients from controls [18]. Therefore, the main objective of this work is to validate the diagnostic accuracy of a normalized CSF biomarker index, the AD-CSF-index, in different European populations and with different methods of detection for CSF biomarkers. MATERIAL AND METHODS Subjects Subjects were recruited from four experienced European memory clinics from September 2009 to April All subjects underwent clinical and neuropsychological assessment, lumbar puncture and CSF analysis at the local laboratory. The study was approved by the local ethics committee and all participants gave written informed consent to participate in the study. A total of 341 subjects, 103 controls and 238 AD patients, were included: 78 participants (44 controls, 34 AD patients) were consecutively recruited at the Alzheimer s Ddisease and other Cognitive Disorders Unit, from the Hospital Clinic i Universitari, Barcelona (Site 1); 59 participants (12 controls, 47 AD patients) were consecutively recruited from the Memory Unit, from the Sant Pau Hospital, Barcelona (Site 2); 60 participants (60 AD patients) were consecutively recruited from the Salpetriere (Site 3); 145 participants (47 controls, 98 AD patients) were consecutively recruited from the memory clinic of the University of at Bonn Medical Centre (Site 4). Normal controls were defined as cognitive healthy elderly that presented no cognitive complaints and no evidence of cognitive impairment (below 1.5 standard deviations) in any of the neuropsychological tests administered. They were recruited as research volunteers and thoughtfully studied at each memory clinic. AD patients were diagnosed according to the NINCDS-ADRDA criteria. All patients included were in the mild and moderate stage of the disease. Clinical diagnoses were made independently of the CSF results. The demographic characteristics of the population studied are shown in Table 1.
3 J.L. Molinuevo et al. / Validation of the AD-CSF-Index 69 Table 1 Demographic characteristics of the studied population Clinic St. Pau Bonn Paris Control AD Control AD Control AD AD mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) mean (SD) Age 65.6 (9.0) 67.6 (9.2) 63.5 (8.1) 70.3 (8.1) 66.7 (11.3) 71.3 (8.5) 65.0 (9.8) Gender (% female) 50% 64.8% 33.3% 66.7% 26.7% 42.3% 51.7% Education (y) 10.7 (4.5) 8.7 (3.4) 11.6 (4.4) 9.5 (4.6) 14.1 (3.5) 11.7 (3.4) 9.8 (5.1) MMSE 28.5 (1.4) 22.7 (4.1) 28.9 (0.9) 21.2 (7.4) 26.1 (5.4) 21.1 (5.4) 20.0 (5.4) CDR 0.06 (0.0) 3.6 (2.0) 0 (0) 0.9 (0.4) n.a. n.a. n.a. APOE % % 53.7% 16.7% 52.1% n.a. n.a. n.a. p < SD, standard deviation; n.a., not available; MMSE, Mini-Mental Status Exam; CDR, Clinical Dementia Rating. CSF analyses and AD-CSF-index calculation Subjects underwent lumbar puncture between 9 12 am and 10 ml of CSF was collected in polypropylene tubes. The samples were centrifuged and stored within the first hour after lumbar puncture in polypropylene tubes at 80 C. Levels of A 1-42, t-tau, and p- tau were measured by enzyme-linked immunosorbent assay (ELISA) kits (Innogenetics, Ghent, Belgium) in three centers, Hospital Clinic and Sant Pau Hospital in Barcelona, and the Salpetiere in Paris, and by Meso Scale Discovery electrochemoluminescence detection (Meso Scale Discovery, MSD, Gaithersburg, MD, in Bonn [19]. The AD-CSF-index was calculated as previously published [18]. In summary from each subject s A 1-42, p-tau, and t-tau values, the index was calculated applying the following formula: AD CSF Index (t tau) = Aβ max Aβ 1 42 Aβ max Aβ min + ttau ttau min ttau max ttau min (1) AD CSF Index (p tau)= Aβ max Aβ 1 42 Aβ max Aβ min + ptau ptau min ptau max ptau min (2) where A max, ttau max, and ptau max represent the 95th percentile of the respective values; A min, ttau min, and ptau min represent the 5th percentile of the distribution values; and A 1-42, ttau, and ptau represent the biomarker values for every individual. Derivation of useful and representative minimum and maximum values of the biomarkers was based on the 5th and 95th percentiles of their respective distributions in two different ways: either calculated separately for every site s data or after pooling the different samples (Table 2). Therefore, four different versions of the AD-CSFindex have been generated as a function of whether t-tau and p-tau values were used and whether intra-site (normalized) or inter-site (pooled) 5th and 95th percentiles have been applied to Equation 1. Pooling MesoScaleDiscovery (Bonn) and ELISA (rest of sites) values together could potentially bias the performance of the AD-CSF-index. Therefore, prior to proceeding with the joint analysis of the data from the four sites, a comparison of the performance of the AD-CSF-index between the two techniques was carried out (Table 3). Statistical analysis Statistical analyses were performed with the SPSS package for Windows (V.17.0) and MatLab The diagnostic power of the AD-CSF-index in the sample was compared to that of the individual CSF biomarkers and to other composite indices which are commonly used like the ratio tau/a 1-42 and the index described by Hulstaert [8], computed as A 1-42 /( *tau). The diagnostic power of the different biomarkers and progression indices for discriminating AD patients from controls was evaluated by receiving operating characteristic (ROC) analysis and by logistic regression. The ROC analysis consisted of the calculation of the area under the curve (AUC) for all the CSF biomarkers and progression indices. Additionally, the sensitivity at 85% specificity along with the respective cut-off values were also recorded as this parameter is often presented as a quality criterion. For each index, we assessed with logistic regression the percentage of correctly classified cases, the respective cut-off value and the resulting sensitivity and specificity, and the model fit as measured by Nagelkerke s R 2. In logistic regression analysis, we also included two bivariate models formed by simultaneously entering as covariates A 1-42 and t-tau, and A 1-42 and p-tau.
4 70 J.L. Molinuevo et al. / Validation of the AD-CSF-Index Table 2 5th and 95th percentiles of the CSF biomarkers at the four sites Site n (Control + AD) A 1-42 (pg/ml) t-tau (pg/ml) p-tau (pg/ml) 5% 95% 5% 95% 5% 95% Bonn a 145 ( ) Paris b 59 (0 + 59) St. Pau 59 ( ) Clínic 78 ( ) Pooled 341 ( ) a Values in mesoscale; b Only AD patients included in this sample. In order to improve the generality of the results of the ROC and logistic regressions analyses, we adopted a resampling scheme. Samples were randomly split: one half was used to derive the corresponding minimum and maximum values for the AD-CSF-index as previously described, and the other half was used to perform the analyses. As this process provides a dispersion of results depending on which cases fall into each split, the process was repeated 1000 times. Median values are reported, as well as 95% confidence intervals (95% CI), calculated as the 5th and 95th percentiles of the resampling distributions. Statistical significance between two particular tests is established if the respective 95% CIs do not overlap. This criterion can be considered as the resampling equivalent to a non-parametric test for the comparison of the means of two independent samples with a statistical significance threshold of p < Between AD patients and controls, the effect size achieved by the different biomarkers and progression indices was assessed by calculating their respective Cohen s d and Student s t values. Higher absolute Cohen s d and Student s t values are indicative of higher effect sizes and, thus, higher statistical power in between-group analyses. Additionally in the control group, a correlation analysis was performed between the CSF biomarkers and progression indices versus Age as the main risk factor for developing AD. Pearson s r was computed for all CSF biomarkers and composite indices. RESULTS Descriptive statistics Mean and standard deviations of the quantifications of the CSF biomarkers for the four different sites are shown in Table 4 and Fig. 1. The investigation of statistically significant differences among these values falls beyond the scope of this article and are only shown for descriptive purposes. As expected, A 1-42 values of the Bonn site were higher than those of the other sites for controls and AD cases. This result parallels a previous analysis, where the detection by the electrochemoluminescence based MesoScaleDiscovery system showed a tendency toward higher levels as compared to ELISA detection [19]. While the exact reason for this phenomenon remains unclear, one may hypothesize that the electrochemoluminescence detection may be more sensitive than an ELISA based detection. Four different versions of the AD-CSF-index were calculated, as indicated in Equation 1, by using t- tau or p-tau and either the site-normalized or pooled minimum and maximum values in Table 2. The performance of the AD-CSF-index was independent of the method for quantification of the CSF biomarkers. We compared the performance of the indices between the site using MesoScaleDiscovery (Bonn) and the other sites using ELISA. Qualitatively, both methods for the quantification of the CSF biomarkers achieved a very similar performance (Table 3). These results support the appropriateness of analyzing pooled ELISA and MesoScaleDiscovery derived data for a unified analysis in the sample. Comparison of discrimination power The ROC analysis (Fig. 3) showed that the normalized versions of the AD-CSF-index clearly presented the best AUC values among all tested diagnostic indices. Indeed their AUC was significantly higher (p < 0.05) than that of A 1-42 and p-tau biomarkers (Table 5). Regarding the comparison between intra-site normalized and inter-site pooled versions of the AD- CSF-index, the first performed better than the pooled versions, as expected. However, these differences did not reach statistical significance. Nevertheless, the latter showed a similar performance than tau over A 1-42 ratios or the Hulstaert indices (Table 5). Again, no statistically significant differences could be detected between them. The logistic regression analysis confirmed this pattern as the normalized versions of the AD-CSF-index
5 J.L. Molinuevo et al. / Validation of the AD-CSF-Index 71 Table 3 Comparison of the performance of ELISA and MesoScale derived AD-CSF-indices calculated using 5th and 95th percentiles of the pooled and individual distribution values Index Technique ROC Analysis Logistic regression AUC 85% Spec [%] Cut-off corr class [%] Model Fit Cut-off Max/min values derived from pooled distribution values (Max: 95th percentile; Min: 5th percentile) AD-CSF-index (t-tau) MesoScale ELISA AD-CSF-index (p-tau) MesoScale ELISA Max/min values derived from respective distribution values (Max: 95th percentile; Min: 5th percentile) AD-CSF-index (t-tau) MesoScale ELISA AD-CSF-index (p-tau) MesoScale ELISA Diagnosis AD CON Errorbars indicate Standard Deviations Abeta bonn clinic paris stpau ttau ptau bonn clinic paris stpau bonn clinic paris stpau Fig. 1. Mean (SD) values of the CSF biomarkers (in pg/ml) obtained at the four different sites. presented the highest percentage of correctly classified cases and the best model fits and performed significantly better than all the individual biomarkers and the Hulstaert (p-tau). In addition, the AD-CSFindex (t-tau) did perform significantly better than the p-tau/a 1-42 ratio. With regards to the rest of the
6 72 J.L. Molinuevo et al. / Validation of the AD-CSF-Index Fig. 2. Distribution of the A 1-42 and p-tau values and coded by referring site and diagnosis. Table 4 Mean (SD) values of the CSF biomarkers obtained at the four different sites Bonn a Paris St. Pau Clínic mean (SD) mean (SD) mean (SD) mean (SD) A 1-42 (pg/ml) AD (285.47) (96.63) (173.74) (66.96) Control (470.50) (221.80) (224.32) t-tau (pg/ml) AD (604.66) (311.99) (360.77) (467.33) Control (242.29) (53.48) (325.01) p-tau (pg/ml) AD (33.31) (36.23) (29.55) (49.56) Control (23.49) (10.14) (34.95) a Values in mesoscale. SD, standard deviation. indices, the pooled AD-CSF-index (t-tau) and the Hulstaert (t-tau) achieved similar results and significantly outperformed the individual CSF values. Finally, the pooled AD-CSF-index (p-tau) showed a statistically significant better performance than A 1-42 and p-tau, but not t-tau. In terms of overall classification accuracy, the optimal cutoff points were again very stable, as they ranged from 0.73 to 0.90 for the four versions of the AD-CSF-index (Table 6). The effect size measurements for discriminating between control and AD groups are shown in the Supplementary Table 1 (available online: dx.doi.org/ /jad ). All four versions of the index were significantly (p < 0.001) higher in
7 J.L. Molinuevo et al. / Validation of the AD-CSF-Index 73 Fig. 3. ROC curves for all tested AD progression indices. Please refer to Table 5 for the statistical performance of the different indices. Table 5 Diagnostic power of the AD progression indices based on CSF biomarkers as studied by ROC analysis Index AUC (CI 95%) Sensitivity at 85% specificity [%] Cutoff Value for 85% specificity A ( ) p-tau ( ) t-tau ( ) p-tau/a b ( ) t-tau/a a,b,c ( ) Hulstaert (p-tau) ( ) Hulstaert (t-tau) a,b,c ( ) AD-CSF-index pooled (p-tau) b ( ) AD-CSF-index pooled (t-tau) a,b,c ( ) AD-CSF-index (p-tau) a,b,c,d ( ) AD-CSF-index (t-tau) a,b,c,d ( ) a AUC significantly higher (p < 0.05) than A 1-42 ; b AUC significantly higher (p < 0.05) than p-tau; c AUC significantly higher (p < 0.05) than t-tau; d AUC significantly higher (p < 0.05) than Hulstaert (p-tau). AD patients than in controls (pooled (p-tau): control = , AD = ; pooled (t-tau): control = , AD = ; normalized (p-tau): control = , AD = ; normalized (t-tau): control = , AD = ) as well as the rest of progression indices and CSF biomarkers except for the A 1-42 values and Hulstaert indices which were significantly lower. However, the AD-CSF-index presented with the highest effect sizes of all the studied indices. The AD-CSF-index values also presented the strongest association with the age of controls among all tested methods: AD-CSF-index (p-tau) r = (p < 0.001) and AD-CSF-index (t-tau) r = (p < 0.001) (Supplementary Table 2). DISCUSSION The results from this study show that the AD- CSF-index represents a novel approach, combining normalized CSF determined A and t-tau or p- tau values, for the biological diagnosis of AD. The AD-CSF-index presents an optimal AUC with high sensitivity and specificity and seems to be a simple and intuitive way to interpret AD CSF biomarkers results. One of the limitations of CSF biomarkers is that the values obtained in one laboratory may be different from those obtained in another lab. Even when using the same assay, considerable variability in absolute concentrations of AD biomarkers has been found
8 74 J.L. Molinuevo et al. / Validation of the AD-CSF-Index Table 6 Diagnostic power and cut-off values of the AD progression indices based on CSF biomarkers as determined by logistic regression Index Cases Model fit Cut-off Sensitivity Specificity correctly classified [Nagelkerke s R 2 ] value at cut-off at cut-off [%] (CI 95%) (CI 95%) value [%] value [%] A ( ) ( ) p-tau ( ) ( ) t-tau ( ) ( ) A 1-42 & p-tau (bivariate model) ( ) ( ) A 1-42 & t-tau (bivariate model) b ( ) ( ) p-tau/ A ( ) ( ) t-tau/ A 1-42b ( ) ( ) Hulstaert (p-tau) ( ) ( ) Hulstaert (t-tau) a,b,c,d ( ) ( ) AD-CSF-index pooled (p-tau) a,b ( ) ( ) AD-CSF-index pooled (t-tau) a,b,c ( ) ( ) AD-CSF-index (p-tau) a,b,c,d,e ( ) ( ) AD-CSF-index (t-tau) a,b,c,d,e ( ) ( ) a Percentage of cases correctly classified significantly higher (p < 0.05) than A 1-42 ; b Percentage of cases correctly classified significantly higher (p < 0.05) than p-tau; c Percentage of cases correctly classified significantly higher (p < 0.05) than t-tau; d Percentage of cases correctly classified significantly higher (p < 0.05) than A 1-42 & p-tau (bivariate model); e Percentage of cases correctly classified significantly higher (p < 0.05) than Hulstaert (p-tau). due to pre-analytical and analytical factors [19]. Furthermore, several studies have shown that the CSF results obtained from different analytical platforms provide very different values [14, 20]. The lack of standardized cut-off values for the diagnosis of AD hampers widespread application of CSF biomarkers for diagnostic purposes in the clinical setting [21]. The development of an index that normalizes the CSF biomarker results among different techniques, laboratories, or populations and that simultaneously captures the pathophysiological relevant changes of CSF A and tau levels may be a useful start for harmonizing AD CSF biomarker interpretation. In this study, we demonstrated that the AD-CSFindex resulted in similar AUC and diagnostic accuracy values although biomarker data were obtained through ELISA and electrochemoluminescence detection. Although the raw A values coming from the ELISA and mesoscale platform were significantly different, the AD-CSF-index was able to normalize them. Its performance with the luminex X-MAP platform is still to be determined. The AD-CSF-index constitutes a valuable alternative to other indices or diagnostic approximations previously described [8, 22 24]. The AD-CSF-index yields a higher diagnostic power and provides stable cut-off points associated with particular sensitivity/specificity values. With respect to diagnostic power, the normalized versions of the AD-CSF-index and particularly the version implementing p-tau values, showed significantly higher diagnostic power than the individual biomarkers or the rest of studied indices. Even the pooled versions were among the best of all the tested indices in our comparisons. Regarding the stability of the cut-off points, although far from reaching a common cut-off point, the AD-CSF-index performed consistently, since cutoff values of approximately 0.75 provided the lowest achievable overall classification errors and cut-off points of about 0.95, specificities around 85%. Whenever pre-analytical and analytical conditions will be fully harmonized, the AD-CSF-index could be a simple way to establish a cut-off point in order to differentiate controls from AD patients. In that sense, there is an urgent need to standardize pre-analytical and analytical factors and to provide reference materials, so that analytical methods and platforms would be harmonized. Another advantage is that the AD-CSF-index adapts to specific samples by discarding the lowest and highest values into them. In any case, these discarded values are less reliable as, by definition, they tend to fall near the limits of the linear segment of the calibration curves of the biomarker quantification techniques. With respect to other indices [8, 15], the normalization strategy adopted in the AD-CSF-index makes it less sensitive to changes in the absolute values of the biomarkers which are known to significantly vary across quantification techniques. Even in applications in which only a few samples are available, our validation shows that the AD-CSF-index is fairly insensitive to changes in the minimum and maximum values
9 J.L. Molinuevo et al. / Validation of the AD-CSF-Index 75 applied into Equation 1 [18]. Moreover, Table 1 provides reference values that can be used for research groups using MesoScale or ELISA CSF determination methods. Another possibility in order to create a formula for generalized use consists of selecting the minimum and maximum quantifiable values from the calibration curve provided by the quantification method or by the laboratory performing the analysis. These values are routinely estimated as a part of the Good Laboratory Practices mandatory for this kind of analytic procedures. Its ease of use together with the excellent AUC suggests that the AD-CSF-index may help to offer CSF analysis its optimal biomarker value [25]. From a pathophysiological perspective, the AD- CSF-index represents a simple way of determining the progression of the biological continuum of AD [26]. Currently, the pathophysiological process of AD and its clinical symptomatology are best conceptualized as a continuum from completely asymptomatic individuals with biomarker evidence suggestive of AD to predementia or prodromal AD patients and ending with a full blown dementia picture [27 29]. In that sense, since the AD-CSF-index is calculated through the addition of normalized CSF determined A and t-tau or p-tau values, it may be able to capture the two main CSF biochemical changes that characterize the AD continuum [26 29]. Actually, the potential of the AD-CSF-index as a descriptor of the AD continuum for research purposes is supported by our results, as they reached the highest effect sizes between AD patients and controls and, in the latter group, the tightest association to age. Therefore, this approximation may be a simple and useful way not only to diagnose the patient but also to determine where in the continuum the patient is located. Nowadays, there is also increasing interest in determining the shape of the trajectories together with the relationship existing among the major AD biomarkers [30]. Since the AD-CSF-index captures the variations of both amyloid and tau, it could be possible to correlate it with the changes observed with other structural markers, such as MRI. In that sense, the AD-CSF-index could be used as a longitudinal, biological, and chronological marker of the CSF alterations ranging from the preclinical stage to mild dementia. Nevertheless, further studies describing the behavior of the AD-CSF-index versus neuropsychological tests and neuroimaging techniques are required to fully confirm this conclusion. Since the publication of the new AD diagnostic criteria in 2007 [4], there has been a lot of discussion on its applicability in a clinical setting [5, 31, 32]. One of the argued drawbacks is the reliability of the different markers [33] and its capacity to differentiate cognitively-preserved elderly from AD patients. It is currently well known that cognitively-preserved elderly may show signs of brain amyloidosis, detected through CSF [34] or A PET imaging [35]. Although its meaning is under debate [36, 37], it is clear that a positive AD CSF profile in order to detect AD with high specificity should include both amyloid and a neuronal injury marker, such as t-tau. This is of remarkable importance if we want to increase the specificity of the diagnosis, and that is the reason for the greater specificity of the AD-CSF-index as compared to A. Furthermore, the A levels by themselves are of little value to determine the proximity of dementia onset, since they may be fully changed even 10 years before dementia onset [38]. We are aware that the study presents several limitations. The study has a cross-sectional design, so its predictive capacity in people with isolated memory or other cognitive deficits that may progress to dementia cannot be addressed. We have also limited the study to two of the existing analytical platforms, so its behavior with Luminex X-MAP driven data is unknown. Further studies should address these questions, together with the association of the index with existing structural changes along the continuum. In summary, the AD-CSF-index represents a novel approximation, combining normalized CSF determined A and t-tau or p-tau values, for the biological diagnosis of AD. The AD-CSF-index presents an optimal AUC with high sensitivity and specificity and seems to be a simple and intuitive way to interpret AD CSF biomarkers results. ACKNOWLEDGMENTS Consolider-Ingenio 2010 (CSD PI: José L Molinuevo); This publication is part of the BIOMARKAPD project within the EU Joint Programme for Neurodegenerative Diseases (JPND) funded by the ISCIII. FIS-Fondo europeo de desarrollo regional, una manera de hacer Europa (PI11/01071 IP: Lorena Rami); proyecto IMSERSO (197/2011 IPD: Lorena Rami); Mapfre company grant (IP: Lorena Rami); programa de investigadores del sistema nacional Miguel Servet (CP 08/00147; IP: Lorena Rami) and the economic support of VALLVERD, S.A Authors disclosures available online (
10 76 J.L. Molinuevo et al. / Validation of the AD-CSF-Index SUPPLEMENTARY MATERIAL Supplementary material can be found here: dx.doi.org/ /jad REFERENCES [1] McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH (2011) The diagnosis of dementia due to Alzheimer s disease: Recommendations from the National Institute on Aging-Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement 7, [2] Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer s Disease Neuroimaging, Initiative (2009) Alzheimer s Disease Neuroimaging Initiative. Cerebrospinal fluid biomarker signature in Alzheimer s disease neuroimaging initiative subjects. Ann Neurol 65, [3] Engelborghs S, De Vreese K, Van de Casteele T, Vanderstichele H, Van Everbroeck B, Cras P, Martin JJ, Vanmechelen E, De Deyn PP (2008) Diagnostic performance of a CSFbiomarker panel in autopsy-confirmed dementia. Neurobiol Aging 29, [4] Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger- Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer s disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, [5] Rami L, Solé-Padullés C, Fortea J, Bosch B, Lladó A, Antonell A, Olives J, Castellví M, Bartres-Faz D, Sánchez- Valle R, Molinuevo JL (2012) Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. Int J Geriatr Psychiatry 27, [6] Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer s Disease Neuroimaging Initiative. (2009) Cerebrospinal fluid biomarker signature in Alzheimer s disease neuroimaging initiative subjects. Ann Neurol 65, , [7] Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased -amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. J Am Med Assoc 289, [8] Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52, [9] Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM (2003) Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289, [10] Blennow K, Vanmechelen E (1998) Combination of the different biological markers for increasing specificity of in vivo Alzheimer s testing. J Neural Transm Suppl 53, [11] Shoji M, Matsubara E, Kanai M, Watanabe M, Nakamura T, Tomidokoro Y, Shizuka M, Wakabayashi K, Igeta Y, Ikeda Y, Mizushima K, Amari M, Ishiguro K, Kawarabayashi T, Harigaya Y, Okamoto K, Hirai S (1998) Combination assay of CSF tau, A beta 1-40 and A beta 1-42(43) as a biochemical marker of Alzheimer s disease. J Neurol Sci 158, [12] Maddalena A, Papassotiropoulos A, Müller-Tillmanns B, Jung HH, Hegi T, Nitsch RM, Hock C (2003) Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to betaamyloid peptide42. Arch Neurol 60, [13] Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A (2002) Cerebrospinal fluid tau and betaamyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch Neurol 59, [14] Fagan AM, Shaw LM, Xiong C, Vanderstichele H, Mintun MA, Trojanowski JQ, Coart E, Morris JC, Holtzman DM (2011) Comparison of analytical platforms for cerebrospinal fluid measures of -amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. Arch Neurol 68, [15] Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, [16] Visser PJ, Verhey F, Knol DL, Mintun MA, Morris JC, Holtzman DM (2009) Prevalence and prognostic value of CSF markers of Alzheimer s disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, [17] Craig-Schapiro R, Kuhn M, Xiong C, Pickering EH, Liu J, Misko TP, Perrin RJ, Bales KR, Soares H, Fagan AM, Holtzman DM (2011) Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer s disease diagnosis and prognosis. PLoS One 6, e [18] Molinuevo JL, Gispert JD, Pujol J, Rojas S, Lladó A, Balasa M, Antonell A, Sánchez-Valle R, Rami L (2012) A new approach to the Alzheimer s disease diagnosis with biomarkers: Description of the AD-CSF-index. Rev Neurol 54, [19] Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K (2011) The Alzheimer s Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement 7, e6. [20] Schipke CG, Prokop S, Heppner FL, Heuser I, Peters O (2011) Comparison of immunosorbent assays for the quantification
11 J.L. Molinuevo et al. / Validation of the AD-CSF-Index 77 of biomarkers for Alzheimer s disease in human cerebrospinal fluid. Dement Geriatr Cogn Disord 31, [21] Hort J, O Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P, Scientist Panel on EFNS, Dementia (2010) EFNS guidelines for the diagnosis and management of Alzheimer s disease. Eur J Neurol 17, [22] Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P (1998) High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch Neurol 55, [23] Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J (2009) Neurochemical dementiadiagnostics: A simple algorithm for interpretation of the CSF biomarkers. J Neural Transm 116, [24] Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ (2007) CSF tau/abeta42 ratio for increased risk of mild cognitive impairment: A follow-up study. Neurology 69, [25] The Ronald and Nancy Reagan Research Institute of the Alzheimer s Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: Molecular and Biochemical Markers of Alzheimer s Disease. Neurobiol Aging 19, [26] Jack CR Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer s pathological cascade. Lancet Neurol 9, [27] Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P (2010) Revising the definition of Alzheimer s disease: A new lexicon. Lancet Neurol 9, [28] Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer s disease: Recommendations from the National Institute on Aging-Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease. Alzheimers Dement 7, [29] Rami L, Fortea J, Bosch B, Solé-Padullés C, Lladó A, Iranzo A, Sánchez-Valle R, Molinuevo JL (2011) Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients. J Alzheimers Dis 23, [30] Jack CR Jr., Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, Kantarci K, Bernstein MA, Senjem ML, Gunter JL, Boeve BF, Trojanowski JQ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Knopman DS; Alzheimer s Disease Neuroimaging Initiative (2012) Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol 69, [31] Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, Barkhof F, van der Flier WM, Scheltens P (2010) New research criteria for the diagnosis of Alzheimer s disease applied in a memory clinic population. Dement Geriatr Cogn Disord 30, 1-7. [32] Galluzzi S, Ghidoni R, Paghera B, Amicucci G, Bonetti M, Zanetti O, Cotelli M, Gennarelli M, Frisoni GB; Translational Outpatient Memory Clinic Working Group (2010) The new Alzheimer s criteria in a naturalistic series of patients with mild cognitive impairment. J Neurol 257, [33] Foster NL (2007) A new framework for the diagnosis of Alzheimer s disease. Lancet Neurol 6, [34] Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sánchez- Valle R, Iranzo A, Molinuevo JL, Lladó A (2011) Different profiles of Alzheimer s disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 118, [35] Mintun MA, Larossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC (2006) [11C]PIB in nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67, [36] Hulette CM, Welsh-Bohmer KA, Murray MG, Saunders AM, Mash DC, McIntyre LM (1998) Neuropathological and neuropsychological changes in normal aging: Evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 57, [37] Molinuevo JL, Sánchez-Valle R, Lladó A, Fortea J, Bartrés- Faz D, Rami L (2011) Identifying earlier Alzheimer s disease: Insights from the preclinical and prodromal phases. Neurodegener Dis 10, [38] Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of -amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69,
How can the new diagnostic criteria improve patient selection for DM therapy trials
How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)
More informationUse of cerebrospinal fluid biomarker analysis for improving Alzheimer s disease diagnosis in a non-specialized setting
Research Paper Acta Neurobiol Exp 2012, 72: 264 271 Use of cerebrospinal fluid biomarker analysis for improving Alzheimer s disease diagnosis in a non-specialized setting Martina Malnar 1#, Marko Kosicek
More informationChanging diagnostic criteria for AD - Impact on Clinical trials
Changing diagnostic criteria for AD - Impact on Clinical trials London, November 2014 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière Hospital
More informationThe added value of the IWG-2 diagnostic criteria for Alzheimer s disease
The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière
More informationAgreed by Scientific Advice Working Party January Adoption by CHMP for release for consultation 20 January 2011
14 April 2011 EMA/CHMP/SAWP/102001/2011 Procedure No.: EMEA/H/SAB/005/1/QA/2010 Committee for Medicinal Products for Human Use (CHMP) Qualification opinion of novel methodologies in the predementia stage
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a postprint version which may differ from the publisher's version. For additional information about this
More informationAPPENDIX SUPPLEMENTARY METHODS Control group criteria for each center... 2 strem2 ELISA protocol... 3 APPENDIX TABLES... 4
APPENDIX Content APPENDIX SUPPLEMENTARY METHODS... 2 Control group criteria for each center... 2 strem2 ELISA protocol... 3 APPENDIX TABLES... 4 Appendix Table S1. CSF core biomarkers cut-offs for each
More informationNew lexicon and criteria for the diagnosis of Alzheimer's disease
Edith Cowan University Research Online ECU Publications Pre. 2011 2011 New lexicon and criteria for the diagnosis of Alzheimer's disease Hamid Sohrabi Edith Cowan University Michael Weinborn Johanna Badcock
More informationNeurology for the Non Neurologist
ADC Administrators Meeting Vancouver, BC April 18, 2016 Neurology for the Non Neurologist Steven T. DeKosky, MD, FACP, FAAN Interim Executive Director, McKnight Brain Institute Aerts/Cosper Professor of
More informationBiochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to -Amyloid Peptide 42
ORIGINAL CONTRIBUTION Biochemical Diagnosis of Alzheimer Disease by Measuring the Cerebrospinal Fluid Ratio of Phosphorylated tau Protein to -Amyloid Peptide 42 Alessia Maddalena, MD; Andreas Papassotiropoulos,
More informationBiomarkers for Alzheimer s disease
Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer
More informationDND. The Correlation Study between Plasma Aβ Proteins and Cerebrospinal Fluid Alzheimer s Disease Biomarkers INTRODUCTION
Print ISSN 1738-1495 / On-line ISSN 2384-0757 Dement Neurocogn Disord 2016;15(4):122-128 / https://doi.org/10.12779/dnd.2016.15.4.122 ORIGINAL ARTICLE DND The Correlation Study between Plasma Aβ Proteins
More informationCerebrospinal Fluid Biomarker Signature in Alzheimer s Disease Neuroimaging Initiative Subjects
Cerebrospinal Fluid Biomarker Signature in Alzheimer s Disease Neuroimaging Initiative Subjects Leslie M. Shaw, PhD, 1 Hugo Vanderstichele, PhD, 2 Malgorzata Knapik-Czajka, PhD, 1 Christopher M. Clark,
More informationOriginal Article Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer s disease
Am J Neurodegener Dis 2014;3(3):143-151 www.ajnd.us /ISSN:2165-591X/AJND0002095 Original Article Comparison of two methods for the analysis of CSF Aβ and tau in the diagnosis of Alzheimer s disease Matthew
More informationV. Senanarong, N. Siwasariyanon, L. Washirutmangkur, N. Poungvarin, C. Ratanabunakit, N. Aoonkaew, and S. Udomphanthurak
International Alzheimer s Disease Volume 2012, Article ID 212063, 5 pages doi:10.1155/2012/212063 Research Article Alzheimer s Disease Dementia as the Diagnosis Best Supported by the Cerebrospinal Fluid
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/89985
More informationORIGINAL CONTRIBUTION. Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum
ORIGINAL CONTRIBUTION Cerebrospinal Fluid Abnormalities and Rate of Decline in Everyday Function Across the Dementia Spectrum Normal Aging, Mild Cognitive Impairment, and Alzheimer Disease Ozioma C. Okonkwo,
More informationORIGINAL CONTRIBUTION. Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnestic Mild Cognitive Impairment Ozioma C. Okonkwo, PhD; Michelle M. Mielke, PhD; H. Randall Griffith,
More informationORIGINAL CONTRIBUTION. Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults
ORIGINAL CONTRIBUTION Correlation of Longitudinal Cerebrospinal Fluid Biomarkers With Cognitive Decline in Healthy Older Adults Erik Stomrud, MD; Oskar Hansson, MD, PhD; Henrik Zetterberg, MD, PhD; Kaj
More informationConcept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease and other dementias
15 March 20122 EMA/CHMP/60715/2012 Committee for Medicinal Products for Human Use (CHMP) Concept paper on no need for revision of the guideline on medicinal products for the treatment of Alzheimer's disease
More informationUnbiased estimates of cerebrospinal fluid β-amyloid 1 42 cutoffs in a large memory clinic population
Bertens et al. Alzheimer's Research & Therapy (2017) 9:8 DOI 10.1186/s13195-016-0233-7 RESEARCH Unbiased estimates of cerebrospinal fluid β-amyloid 1 42 cutoffs in a large memory clinic population Daniela
More informationClinical Study Influence of APOE Genotype on Alzheimer s Disease CSF Biomarkers in a Spanish Population
BioMed Research International Volume 20, Article ID 1390620, 7 pages http://dx.doi.org/10.1155/20/1390620 Clinical Study Influence of APOE Genotype on Alzheimer s Disease CSF Biomarkers in a Spanish Population
More informationImpact of cerebro-spinal fluid biomarkers of Alzheimer s disease in clinical practice: a multicentric study
DOI 10.1007/s00415-013-7160-3 ORIGINAL COMMUNICATION Impact of cerebro-spinal fluid biomarkers of Alzheimer s disease in clinical practice: a multicentric study François Mouton-Liger David Wallon Anne-Cécile
More informationAlzheimer CSF biomarkers in routine clinical setting
Acta Neurol Scand DOI: 1.1111/j.16-44.211.1592.x Ó 211 John Wiley & Sons A S ACTA NEUROLOGICA SCANDINAVICA Alzheimer CSF biomarkers in routine clinical setting Tabaraud F, Leman JP, Milor AM, Roussie JM,
More informationRosen, Christoffer; Hansson, Oskar; Blennow, Kaj; Zetterberg, Henrik
Fluid biomarkers in Alzheimer's disease - current concepts Rosen, Christoffer; Hansson, Oskar; Blennow, Kaj; Zetterberg, Henrik Published in: Molecular Neurodegeneration DOI: 10.1186/1750-1326-8-20 2013
More informationAlzheimer s disease diagnostic criteria: practical applications
REVIEW Alzheimer s disease diagnostic criteria: practical applications Jeffrey Cummings* Abstract Alzheimer s disease (AD) can be identified prior to the occurrence of dementia by using biomarkers. Three
More informationCSF Aβ1-42 predicts cognitive impairment in de novo PD patients
CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2
More informationUnbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid Analysis Results
Papers in Press. Published December 5, 2017 as doi:10.1373/clinchem.2017.281055 The latest version is at http://hwmaint.clinchem.aaccjnls.org/cgi/doi/10.1373/clinchem.2017.281055 Clinical Chemistry 64:3
More informationREVIEW. Howard Chertkow* 1,2, Howard H Feldman 3, Claudia Jacova 4 and Fadi Massoud 5. Abstract
REVIEW Definitions of dementia and predementia states in Alzheimer s disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia Howard Chertkow* 1,2, Howard
More informationEngineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos,
Engineering team: Andrew Lang, Bo Liu, Jerry Prince, Brian Caffo, Murat bilgel, Runze Tan, Chun-Guang, and Zhou Ye; Medical team: Kostas Lyketsos, Susan Resnik, Sterling Johnson, and Pierre Jedynak Longitudinal
More informationEvaluation of Plasma A beta as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study
Evaluation of Plasma A beta as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study Hansson, Oskar; Stomrud, Erik; Vanmechelen, Eugeen; Ostling, Svante; Gustafson,
More informationNIH Public Access Author Manuscript Neuromolecular Med. Author manuscript; available in PMC 2012 March 1.
NIH Public Access Author Manuscript Published in final edited form as: Neuromolecular Med. 2011 March ; 13(1): 37 43. doi:10.1007/s12017-010-8126-6. Increased Cerebrospinal Fluid F 2 -Isoprostanes are
More informationEarly Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods. Christos Davatzikos, Ph.D.
Early Diagnosis of Alzheimer s Disease and MCI via Imaging and Pattern Analysis Methods Christos Davatzikos, Ph.D. Director, Section of Biomedical Image Analysis Professor of Radiology http://www.rad.upenn.edu/sbia
More informationORIGINAL CONTRIBUTION. Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic
ORIGINAL CONTRIBUTION Cerebrospinal Fluid -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain Tero Tapiola, MD, PhD; Irina Alafuzoff, MD, PhD; Sanna-Kaisa Herukka,
More informationJingami, Naoto; Asada-Utsugi, Megum Author(s) Noto, Rio; Takahashi, Makio; Ozaki, Takeshi; Kageyama, Takashi; Takahas Shimohama, Shun; Kinoshita, Ayae
Idiopathic Normal Pressure Hydrocep TitleCerebrospinal Fluid Biomarker Profi Disease. Jingami, Naoto; Asada-Utsugi, Megum Author(s) Noto, Rio; Takahashi, Makio; Ozaki, Takeshi; Kageyama, Takashi; Takahas
More informationLongitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer s disease: A prospective 9-year study
Alzheimer s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 403-411 CSF Biomarkers Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer s disease: A
More informationImproving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018
Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been
More informationMRI and CSF biomarkers in normal, MCI, and AD subjects Predicting future clinical change
MRI and CSF biomarkers in normal, MCI, and AD subjects Predicting future clinical change P. Vemuri, PhD H.J. Wiste, BA S.D. Weigand, MS L.M. Shaw, PhD J.Q. Trojanowski, MD M.W. Weiner, MD D.S. Knopman,
More informationStandardization efforts for Alzheimer CSF biomarkers, and Plasma neurofilament light (NFL) as a biomarker for AD
Standardization efforts for Alzheimer CSF biomarkers, and Plasma neurofilament light (NFL) as a biomarker for AD Kaj Blennow, Professor Academic Chair in Neurochemistry, University of Gothenburg The Söderberg
More informationThe Rationale Behind the New Alzheimer s Disease Conceptualization: Lessons Learned During the Last Decades
Journal of Alzheimer s Disease 62 (2018) 1067 1077 DOI 10.3233/JAD-170698 IOS Press Review 1067 The Rationale Behind the New Alzheimer s Disease Conceptualization: Lessons Learned During the Last Decades
More informationADNI Biomarker Core. WWADNI meeting, Boston, MA, July 12, 2013
ADNI Biomarker Core Leslie M Shaw and John Q Trojanowski Department of Pathology & Laboratory Medicine Perelman School of Medicine University of Pennsylvania WWADNI meeting, Boston, MA, July 12, 2013 ADNI
More informationOutline. Facts and figures Action plans Early / correct diagnosis Conclusions
Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam
More informationRisk Factors for Post-Lumbar Puncture Headache in a Study of Alzheimer s Disease Biomarkers
Print ISSN 1738-1495 / On-line ISSN 2384-0757 Dement Neurocogn Disord 2015;14(1):12-16 / http://dx.doi.org/10.12779/dnd.2015.14.1.12 ORIGINAL ARTICLE DND in a Study of Alzheimer s Disease Biomarkers So
More informationImplementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative
Implementation of fully automated immunoassays for CSF Aβ 1-42, t-tau and p-tau 181 in the Alzheimer s Disease Neuroimaging Initiative Leslie M Shaw Perelman School of Medicine, University of Pennsylvania
More informationAn integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease
An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech
More informationORIGINAL CONTRIBUTION. Plasma and Cerebrospinal Fluid Levels of Amyloid Proteins 1-40 and 1-42 in Alzheimer Disease
ORIGINAL CONTRIBUTION Plasma and Cerebrospinal Fluid Levels of Amyloid Proteins 1-40 and 1-42 in Alzheimer Disease Pankaj D. Mehta, PhD; Tuula Pirttilä, MD, PhD; Sangita P. Mehta, MS; Eugene A. Sersen,
More informationNEXT-Link DEMENTIA. A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES.
NEXT-Link DEMENTIA A network of Danish memory clinics YOUR CLINICAL RESEARCH PARTNER WITHIN ALZHEIMER S DISEASE AND OTHER DEMENTIA DISEASES. NEXT-Link DEMENTIA NEXT-Link DEMENTIA is a network of Danish
More informationNIH Public Access Author Manuscript Alzheimers Dement. Author manuscript; available in PMC 2012 March 25.
NIH Public Access Author Manuscript Published in final edited form as: Alzheimers Dement. 2011 May ; 7(3): 263 269. doi:10.1016/j.jalz.2011.03.005. The diagnosis of dementia due to Alzheimer s disease:
More informationNeuroinflammation in preclinical AD: in vivo evidence
Neuroinflammation in preclinical AD: in vivo evidence Barbara Bendlin, PhD Assistant Professor UW-Madison Dept. of Medicine, Geriatrics bbb@medicine.wisc.edu Overview Background Preclinical effects of
More informationHuman Neurology 3-Plex A
Human Neurology 3-Plex A SUMMARY AND EXPLANATION OF THE TEST The Human N3PA assay is a digital immunoassay for the quantitative determination of total Tau, Aβ42, and Aβ40 in human plasma and CSF. Determination
More informationCCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer s Disease
CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer s Disease Karin Westin 1,2, Peder Buchhave 1,2, Henrietta Nielsen 1,3, Lennart Minthon 1,2, Sabina Janciauskiene
More informationDementia, Cognitive Aging Services and Support
Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,
More informationORIGINAL CONTRIBUTION. Evaluation of CSF-tau and CSF-A 42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
ORIGINAL CONTRIBUTION Evaluation of CSF-tau and CSF-A 42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice Niels Andreasen, MD, PhD; Lennart Minthon, MD, PhD; Pia Davidsson, PhD; Eugeen
More informationUPDATE ON MILD COGNITIVE IMPAIRMENT
UPDATE ON MILD COGNITIVE IMPAIRMENT Ronald C. Petersen, PhD, MD Mayo Clinic College of Medicine Rochester, MN David Gill, MD University of Rochester Rochester, NY Introduction Mild cognitive impairment
More informationNew diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist
New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA
More informationMild Cognitive Impairment (MCI)
October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine
More information1. Introduction. 2. Patients and Methods
SAGE-Hindawi Access to Research International Journal of Alzheimer s Disease Volume 200, Article ID 7657, 7 pages doi:0.406/200/7657 Research Article Combined Analysis of CSF Tau, Aβ42, Aβ 42% and Aβ 40
More informationSerum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer s disease
Sánchez-Valle et al. Alzheimer's Research & Therapy (2018) 10:113 https://doi.org/10.1186/s13195-018-0439-y RESEARCH Open Access Serum neurofilament light levels correlate with severity measures and neurodegeneration
More informationRecent publications using the NACC Database. Lilah Besser
Recent publications using the NACC Database Lilah Besser Data requests and publications Using NACC data Number of requests by year Type 2009 2010 2011 2012 2013 2014 2015 Data files* 55 85 217 174 204
More informationThe Reliability and Validity of the Korean Instrumental Activities of Daily Living (K-IADL)
The Reliability and Validity of the Korean Instrumental Activities of Daily Living (K-IADL Sue J. Kang, M.S., Seong Hye Choi, M.D.*, Byung H. Lee, M.A., Jay C. Kwon, M.D., Duk L. Na, M.D., Seol-Heui Han
More informationDISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT
Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease
More information10/30/2018. How do we diagnose dementia? Subtypes of dementia Case Studies
http://www.alz.org/alzheimers_disease_10_signs_of_alzheimers.asp#signs How do we diagnose dementia? Subtypes of dementia Case Studies 1. Memory loss that disrupts daily life Forgetting important dates
More informationUpdate on the biomarker core of the Alzheimer s Disease Neuroimaging Initiative subjects
Alzheimer s & Dementia 6 (2010) 230 238 Update on the biomarker core of the Alzheimer s Disease Neuroimaging Initiative subjects John Q. Trojanowski a, *, Hugo Vandeerstichele b, Magdalena Korecka a, Christopher
More informationBaldeiras et al. Alzheimer's Research & Therapy (2018) 10:33
Baldeiras et al. Alzheimer's Research & Therapy (2018) 10:33 https://doi.org/10.1186/s13195-018-0362-2 RESEARCH Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the
More informationCSF beta-amyloid what are we measuring in Alzheimer's disease?
CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease? William Hu, Emory University Kelly D Watts, Emory University Leslie M Shaw, University of Pennsylvania Jennifer Christina Howell, Emory
More informationRole of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases
Role of TDP-43 in Non-Alzheimer s and Alzheimer s Neurodegenerative Diseases Keith A. Josephs, MD, MST, MSc Professor of Neurology 13th Annual Mild Cognitive Impairment (MCI) Symposium: Alzheimer and Non-Alzheimer
More informationADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development
ADNI Experience on Developing Biomarker Tools as Example of An Approach to Catalyzing Dry AMD Drug Development Wm Z Potter, MD, PhD Sr. Advisor, NIMH IOM, Nov 15, 2014 Disclosures Former employee of Lilly
More informationCognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer s Disease
Journal of Alzheimer s Disease 47 (2015) 205 214 DOI 10.3233/JAD-142508 IOS Press 205 Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer s Disease Hong Liu-Seifert a,, Eric
More informationEstimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale
Estimating the Validity of the Korean Version of Expanded Clinical Dementia Rating (CDR) Scale Seong Hye Choi, M.D.*, Duk L. Na, M.D., Byung Hwa Lee, M.A., Dong-Seog Hahm, M.D., Jee Hyang Jeong, M.D.,
More informationWashington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease
Washington University: Setting the Stage for Secondary Prevention Trials in Alzheimer Disease John C. Morris, MD Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology Disclosure Statement
More informationTHE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME
PERNECZKY 15/06/06 14:35 Page 1 THE ROLE OF ACTIVITIES OF DAILY LIVING IN THE MCI SYNDROME R. PERNECZKY, A. KURZ Department of Psychiatry and Psychotherapy, Technical University of Munich, Germany. Correspondence
More informationDisclosure Statement
Recommendations on MCI from the Third and Fourth Canadian Consensus Conferences on Diagnosis and Therapy of Dementia/ Quatrieme Conférence Canadienne Consensuelle sur la Démence 2012. Dr. Howard Chertkow
More informationORIGINAL CONTRIBUTION. Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment
ORIGINAL CONTRIBUTION Comparison of the Short Test of Mental Status and the Mini-Mental State Examination in Mild Cognitive Impairment David F. Tang-Wai, MDCM; David S. Knopman, MD; Yonas E. Geda, MD;
More informationA Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong
A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong Outline The pathogenesis of Late life cognitive impairment A framework
More informationCOGNITIVE CORRELATES of CEREBROSPINAL FLUID BIOMARKERS for ALZHEIMER S DISEASE
COGNITIVE CORRELATES of CEREBROSPINAL FLUID BIOMARKERS for ALZHEIMER S DISEASE BABETTE L.R. REIJS COLOFON Layout & Cover design: Design Your Thesis, www.designyourthesis.com Printed by: Ridderprint BV,
More informationUSE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013
Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER
More informationPlasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer s disease
Lewczuk et al. Alzheimer's Research & Therapy (2018) 10:71 https://doi.org/10.1186/s13195-018-0404-9 RESEARCH Open Access Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer
More informationIssues to Consider in the Clinical Evaluation and Development of Drugs for Alzheimer s Disease. The University of Tokyo Hospital
Project to Promote the Development of Innovative Pharmaceuticals, Medical Devices, and Regenerative Medical Products (Ministry of Health, Labour, and Welfare) Regulatory Science Research for the Establishment
More informationPATHS TO ALZHEIMER S DISEASE PREVENTION: FROM MODIFIABLE RISK FACTORS TO BIOMARKER ENRICHMENT STRATEGIES
PATHS TO ALZHEIMER S DISEASE PREVENTION: FROM MODIFIABLE RISK FACTORS TO BIOMARKER ENRICHMENT STRATEGIES S. LISTA 1,2, B. DUBOIS 1, H. HAMPEL 1,2 1. Sorbonne Universités, Université Pierre et Marie Curie,
More informationPsychiatry Research 120 (2003) Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany d
Psychiatry Research 120 (2003) 231 238 Cerebrospinal fluid tau levels in Alzheimer s disease are elevated when compared with vascular dementia but do not correlate with measures of cerebral atrophy a a
More informationCerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer s disease in a memory clinic cohort
Kester et al. Alzheimer's Research & Therapy (2015) 7:59 DOI 10.1186/s13195-015-0142-1 RESEARCH Open Access Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor
More informationPapers recently published using NACC data. Lilah Besser, PhD, MSPH
Papers recently published using NACC data Lilah Besser, PhD, MSPH Example publications, 2016-2017 NACC data used Author Year UDS Kielb et al 2017 NP + UDS Sposato et al 2017 MRI + UDS Lange et al 2016
More informationCSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly.
CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly. Stomrud, Erik; Forsberg, Karl-Anton; Hägerström, Douglas; Ryding, Erik; Blennow, Kaj; Zetterberg, Henrik; Minthon, Lennart;
More informationDementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings
Dementia mimicking Alzheimer s disease Owing to a tau mutation: CSF and PET findings Chapter 4.2 N. Tolboom E.L.G.E. Koedam J.M. Schott M. Yaqub M.A. Blankenstein F. Barkhof Y.A.L. Pijnenburg A.A. Lammertsma
More informationMild Cognitive Impairment
T h e n e w e ngl a nd j o u r na l o f m e dic i n e clinical practice Mild Cognitive Impairment Ronald C. Petersen, M.D., Ph.D. This Journal feature begins with a case vignette highlighting a common
More informationDifferential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231
ORIGINAL CONTRIBUTION Differential Diagnosis of Alzheimer Disease With Cerebrospinal Fluid Levels of Tau Protein Phosphorylated at Threonine 231 Katharina Buerger, MD; Raymond Zinkowski, PhD; Stefan J.
More informationCombined CSF tau, p-tau181 and amyloid-b 38/40/42 for diagnosing Alzheimer s disease
J Neural Transm (2009) 116:203 212 DOI 10.1007/s00702-008-0177-6 ALZHEIMER S DISEASE AND RELATED DISORDERS - ORIGINAL ARTICLE Combined CSF tau, p-tau181 and amyloid-b 38/40/42 for diagnosing Alzheimer
More informationMild Cognitive Impairment Symposium January 19 and 20, 2013
Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment
More informationOligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer s disease
Wang et al. Alzheimer's Research & Therapy (2017) 9:98 DOI 10.1186/s13195-017-0324-0 RESEARCH Open Access Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer
More informationStephen Salloway, M.D., M.S. Disclosure of Interest
Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational
More informationMoving Targets: An Update on Diagnosing Dementia in the Clinic
Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures
More informationCSF Phosphorylated Tau in the Diagnosis and Prognosis of Mild Cognitive Impairment and Alzheimer s Disease A Meta-analysis of 51 Studies
CSF Phosphorylated Tau in the Diagnosis and Prognosis of Mild Cognitive Impairment and Alzheimer s Disease A Meta-analysis of 51 Studies Alex J Mitchell To cite this version: Alex J Mitchell. CSF Phosphorylated
More informationBrain imaging for the diagnosis of people with suspected dementia
Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis
More informationCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
ORIGINAL CONTRIBUTION CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment Niklas Mattsson, MD Henrik Zetterberg, MD, PhD Oskar Hansson, MD, PhD Niels Andreasen, MD,
More informationALZHEIMER S DISEASE THERAPEUTIC TRIALS: EU/US TASK FORCE REPORT ON RECRUITMENT, RETENTION, AND METHODOLOGY
15 HAMPEL2_04 LORD_c 16/04/12 12:14 Page339 ALZHEIMER S DISEASE THERAPEUTIC TRIALS: EU/US TASK FORCE REPORT ON RECRUITMENT, RETENTION, AND METHODOLOGY B. VELLAS 1,2,24, H. HAMPEL 3,24, M.E. ROUGE-BUGAT
More informationCAMD Annual Regulatory Science Workshop CSF Biomarker Team Refocusing on Low Hanging Fruit
CAMD Annual Regulatory Science Workshop CSF Biomarker Team Refocusing on Low Hanging Fruit October 19, 2016 Mary Savage, Co-Chair (seeking additional co-chair) Director, Companion Diagnostics Merck & Co.,
More informationEmerging CSF and serum biomarkers in atypical dementia. Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018
Emerging CSF and serum biomarkers in atypical dementia Laksanun Cheewakriengkrai, MD. Phramongkutklao Hospital March 7 th, 2018 Biomarkers A characteristic that is objectively measured and evaluated as
More informationRuolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce
Ruolo dei biomarcatori come criterio di supporto nella diagnostica delle demenze ad esordio precoce ALESSANDRO MARTORANA UOC NEUROLOGIA-CENTRO ALZHEIMER POLICLINICO TOR VERGATA-UNIVERSITÀ DI ROMA TOR VERGATA
More informationImaging of Alzheimer s Disease: State of the Art
July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression
More informationORIGINAL ARTICLE. Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment
ORIGINAL ARTICLE Clinical Prediction of Alzheimer Disease Dementia Across the Spectrum of Mild Cognitive Impairment Bradford C. Dickerson, MD; Reisa A. Sperling, MD; Bradley T. Hyman, MD, PhD; Marilyn
More information